Q3 2024 revenue and net profit grew modestly year-over-year, driven by albumin and coagulation factor sales. Haier Group became the new controlling shareholder, and the company advanced its R&D pipeline and interim dividend plan.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.